In fiscal year (FY) 2025, Medicare fee-for-service (FFS) remained the dominant payer for kidney transplant admissions, though Medicare Advantage (MA) enrollment among individuals with end‑stage renal disease (ESRD) doubled from 2020 to 2024 following the 21st Century Cures Act. A key Medicare initiative is the Increasing Organ Transplant Access (IOTA) Model that incentivizes certain hospitals to increase the number of kidney transplants by maximizing use of deceased donor kidneys, facilitating more living donor transplants, and improving quality of care. In this evolving policy and payer environment, we examined the kidney transplant landscape and assessed kidney transplant admission financial information under the Inpatient Prospective Payment System (IPPS) and hospital internal resource costs for Medicare FFS beneficiaries in FY 2025. We summarized our findings in the form of a detailed infographic, commissioned by Sanofi U.S.

Download the infographic (PDF).

This report was commissioned by Sanofi U.S.